Envista (NYSE:NVST) Downgraded by Wall Street Zen to “Buy”

Wall Street Zen lowered shares of Envista (NYSE:NVST) from a strong-buy rating to a buy rating in a research report sent to investors on Sunday.

A number of other equities analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Envista in a report on Monday, December 29th. Evercore ISI reissued an “outperform” rating on shares of Envista in a report on Friday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 16th. Mizuho set a $19.00 price target on shares of Envista in a research note on Monday, November 3rd. Finally, Stifel Nicolaus set a $25.00 price objective on Envista in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and an average price target of $21.77.

Envista Stock Up 2.2%

Shares of Envista stock opened at $25.24 on Friday. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of 280.48, a PEG ratio of 1.13 and a beta of 0.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02. Envista has a 1 year low of $14.22 and a 1 year high of $25.41. The company has a 50-day moving average of $21.49 and a 200 day moving average of $20.79.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 29th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $669.90 million for the quarter, compared to analysts’ expectations of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 earnings per share. As a group, sell-side analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in Envista by 26.6% in the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock worth $401,000 after purchasing an additional 4,885 shares during the period. Millennium Management LLC raised its holdings in shares of Envista by 218.6% in the first quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock worth $6,627,000 after buying an additional 263,442 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Envista by 39.3% in the first quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock worth $10,859,000 after buying an additional 177,630 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Envista by 15.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock worth $9,821,000 after acquiring an additional 76,246 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in Envista by 100.1% in the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock valued at $55,000 after acquiring an additional 1,397 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.